Pharmaceuticals

Underdog Launches With $4M to Target “Toxic” Form of Cholesterol

7 monthes ago   |   By Xconomy

Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged with substances such as fats and cholesterol, which restricts blood flow. Based in Mountain View, CA, Underdog is a spinout of the nonprofit SENS Research Foundation. Matthew O'Connor and Michael Kope, SRF's former vice president of research and founding CEO, respectively, are co-founders. The seed round brought in $3.95 million, which the company plans to use in the next 18 months. It will need to raise another...
Read more ...

 


Search by Tags

   Pharmaceuticals      Drug      Drugs      Research      Pharmaceutical      National blog main      San Francisco      San Francisco blog main      Financing      Funding      Healthcare      Life Sciences      Startups  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

After Biologic COVID-19 Drug OK'd in India, Equillium Plans a US Test

After Biologic COVID-19 Drug OK'd in India, Equillium Plans a US Test

The drug that Equillium licensed from India-based pharma giant Biocon has received authorization for emergency use in that country in patients hospitalized with COVID-19. The... Read more ...

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval. The two companies are... Read more ...

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Last Chance for Xconomy Awards Nominations - Deadline is Friday, July 17

Have you had your say yet? The 2020 National Xconomy Awards represent the very best our life science industry has to offer. It is our privilege to recognize emerging companies... Read more ...

New Xconomy Podcast & Special Report Feature Boston Biophama Leaders on...

New Xconomy Podcast & Special Report Feature Boston Biophama Leaders on Digital Health

Miss Xconomy's Xcelerating Life Sciences Boston: Biopharma's Future in Digital Health event or want to revisit the insightful content? Our new podcast and special report... Read more ...

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

At the year's start Thousand Oaks, CA-based Amgen closed a strategic collaboration with BeiGene, investing $2.8 billion to gain a presence in what's becoming an ever-more... Read more ...

Scientists Successfully Demonstrate a New Experiment in the Search for...

Scientists Successfully Demonstrate a New Experiment in the Search for Theorized ‘Neutrinoless' Process

The CUPID-Mo detector is installed in the Edelweiss cryostat at Modane Underground Laboratory in France. Nuclear physicists affiliated with the U.S. Department of Energy's... Read more ...

3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments

3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments

Three biotech companies collectively raised $584 million in their initial public offerings last week, continuing a streak of IPOs that has the healthcare sector playing a... Read more ...

Expression, homology modeling and enzymatic characterization of a new...

Β-mannanase can hydrolyze β-1,4 glycosidic bond of mannan by the manner of endoglycosidase to generate mannan-oligosaccharides. Currently, β-mannanase has been widely applied... Read more ...

De novo resveratrol production through modular engineering of an Escherichia...

Resveratrol is a plant secondary metabolite with diverse, potential health-promoting benefits. Due to its nutraceutical merit, bioproduction of resveratrol via microbial... Read more ...

From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied...

Abstract Alzheimer's disease is one of the most common causes of dementia. It is believed that the aggregation of short Aβ‐peptides to form oligomeric and protofibrillar... Read more ...